Skip to main content
XTNT
NYSE Industrial Applications And Services

Xtant Medical Misses Guidance Again, Withdraws 2026 Outlook and Launches Board Strategic Review

Arie Shkolnikov · Analysis by Wiseek AI
Sentiment info
Negative
Importance info
8
Price
$0.26
Mkt Cap
$38.116M
52W Low
$0.26
52W High
$0.84
52W Position info
0.1% above low
Off High info
69% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

XTNT is trading near its 52-week low of $0.26 (0.1% above the low) on light trading volume (0.1× avg).

Summary

Xtant Medical missed guidance for a second straight quarter, withdrew its 2026 outlook and announced a Board-led strategic review that could include a sale, merger or restructuring. Cash of $7.8M against $22M of debt leaves little room to maneuver.


Key Events · Earnings and Guidance · XTNT

  • Q3 Revenue Falls 27% Year Over Year

    Revenue was $24.3M versus $33.3M in Q3 2025, reflecting the absence of $5.4M of divested Coflex/CoFix and international hardware revenue and $5.5M of prior-year wound care licensing revenue, partly offset by $2.2M of HEMOBLAST sales.

  • Losses Widen, Guidance Withdrawn

    Net loss was $3.6M (-$0.03 per share) versus $1.3M of net income a year earlier, and adjusted EBITDA swung to a $1.5M loss from $4.5M positive. The company said it no longer expects to achieve its previously issued full-year 2026 guidance and is not providing revised guidance.

  • Board Opens Strategic Review

    The Board is evaluating operational improvements, capital structure alternatives, partnerships, restructurings, financings, acquisitions, dispositions and business combinations. No timetable was set and no outcome is assured.

  • Thin Liquidity Against $22M Debt

    As of September 30, 2026 the company had $7.8M of cash, $22M of total indebtedness ($10.2M debt plus $11.8M revolver borrowings) and $2.1M of revolver availability. Management expects cash and availability to fund operations for at least 12 months.


Analysis · XTNT · Industrial Applications And Services

For a second straight quarter, Xtant came in below its own guidance: revenue fell to $24.3M from $33.3M a year ago, and adjusted EBITDA swung to a $1.5M loss from $4.5M positive. Management scrapped full-year 2026 guidance entirely, and the Board opened a strategic review that could end in a sale, merger, restructuring or financing. With only $7.8M of cash against $22M of debt and $2.1M left on the revolver, the company is now explicitly for-sale-or-fix, and the stock sits near its 52-week low. The one bright spot is biologics revenue, up 13% year over year to $19.3M.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XTNT was trading at $0.26 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $38.1M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XTNT - Latest Insights